AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.500

-0.005-0.99%

Volume:67.17K

Turnover:34.14K

Market Cap:108.75M

PE:-4.50

High:0.515

Open:0.510

Low:0.500

Close:0.505

52wk High:0.785

52wk Low:0.350

Shares:217.51M

Float Shares:149.50M

Volume Ratio:0.15

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.111

EPS(LYR):-0.111

ROE:-54.98%

ROA:-31.75%

PB:2.55

PE(LYR):-4.50

Loading ...

Overview Company News Filings

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

THOMSON REUTERS

Alterity Therapeutics Ltd-Alterity Announces Late-Breaker Oral Presentation at Aan

THOMSON REUTERS

Alterity Therapeutics CEO David Allen Stamler files initial beneficial ownership statement

Alterity Therapeutics to host virtual KOL webcast on ATH434 in multiple system atrophy

Alterity Therapeutics director Lawrence Gozlan files initial beneficial ownership statement

Alterity Therapeutics director Julian Michael Babarczy files initial beneficial ownership statement

Alterity Therapeutics director Peter Marks files initial beneficial ownership statement

Alterity Therapeutics CFO Abby Macnish Niven files initial beneficial ownership statement

Alterity Therapeutics Ltd - End-of-Phase 2 FDA Meeting on Track for Mid-2026

THOMSON REUTERS

Alterity Therapeutics Ltd - Receives Positive FDA Feedback Following Type C Meeting on Ath434 Phase 3 Program

THOMSON REUTERS

Alterity Therapeutics Receives Positive FDA Feedback After Type C Meeting on Planned Third-Phase Program

MT Newswires Live

Dogecoin (DOGE) Breaks Price Stalemate as History Signals Worst Is Over: What to Expect

Solana (SOL) Reclaims $90 Amid Golden Cross Setup, Where's Price Heading?

Shibarium Transactions Jump 148% Amid SHIB Price Consolidation

Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/ATH.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.5,"timestamp":1788243120000,"preClose":0.505,"halted":0,"volume":67171,"delay":0,"changeRate":-0.00990099009900991,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"Closed","change":-0.005,"latestTime":"09-01 16:12:00 AEST","open":0.51,"high":0.515,"low":0.5,"amount":34140,"amplitude":0.029703,"askPrice":0.505,"askSize":1819,"bidPrice":0.5,"bidSize":26614,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.505,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":0.146013,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.505,"auctionPrice":0.505,"auctionVolume":105,"auctionTime":1788242445338,"referencePrice":0.5,"referenceTime":1788258603092,"auction":3,"marketStatus":"盘后竞价","timestamp":1788242445338}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-31.75%","roe":"-54.98%","lyrEps":-0.1112,"volumeRatio":0.146013,"shares":217508326,"dividePrice":0,"high":0.515,"amplitude":0.029703,"preClose":0.505,"low":0.5,"week52Low":0.35,"pbRate":"2.55","psRate":"20.42","week52High":0.785,"institutionHeld":0,"latestPrice":0.5,"committee":0.87205,"eps":-0.1112,"divideRate":0,"volume":67171,"delay":0,"ttmEps":-0.1112,"open":0.51,"prevYearClose":0.4,"prevWeekClose":0.52,"prevMonthClose":0.505,"prevQuarterClose":0.575,"fiveDayClose":0.51,"twentyDayClose":0.56,"sixtyDayClose":0.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627292216","title":"Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627292216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627292216?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:25","pubTimestamp":1776338700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA1LZZRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627360250","title":"Alterity Therapeutics Ltd-Alterity Announces Late-Breaker Oral Presentation at Aan","url":"https://stock-news.laohu8.com/highlight/detail?id=2627360250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627360250?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:35","pubTimestamp":1776306920,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUE6TQ4BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627259846","title":"Alterity Therapeutics CEO David Allen Stamler files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627259846","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627259846?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:50","pubTimestamp":1776297016,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics CEO, director David Allen Stamler filed an initial Form 3 reporting 11,688,312 ordinary shares.Filing also listed derivative holdings including options covering up to 290,400,000 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL4rs5HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627228589","title":"Alterity Therapeutics to host virtual KOL webcast on ATH434 in multiple system atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627228589","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627228589?lang=en_us&edition=fundamental","pubTime":"2026-04-15 18:35","pubTimestamp":1776249340,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics will host virtual KOL webcast on ATH434 in multiple system atrophy on April 28, 2026 at 10:00 a.m. Pacific Time.Same event will run for Australia participants on April 29, 2026 at 3:00 a.m. AEST.Webcast will feature Roy Freeman, Daniel Claassen, and Alterity CEO David Stamler.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL285HkW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626319774","title":"Alterity Therapeutics director Lawrence Gozlan files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626319774","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626319774?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:22","pubTimestamp":1775823735,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics director Lawrence Bernard Gozlan filed an initial Form 3 showing indirect ownership of 4,545,455 ordinary shares via Montoya Pty Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL7wvhCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626433197","title":"Alterity Therapeutics director Julian Michael Babarczy files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626433197","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626433197?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:17","pubTimestamp":1775823450,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics filed an initial Form 3 for director Julian Michael Babarczy on April 10, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL4RVgj0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192220","title":"Alterity Therapeutics director Peter Marks files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192220","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626192220?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:57","pubTimestamp":1775822271,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics director Peter Ashley Marks reported indirect ownership of 1,818,182 ordinary shares as of April 10.Marks also disclosed options covering 30,606,061 ordinary shares with exercise prices of $0.01 to $0.03.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL46Z98z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626157359","title":"Alterity Therapeutics CFO Abby Macnish Niven files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626157359","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626157359?lang=en_us&edition=fundamental","pubTime":"2026-04-10 09:59","pubTimestamp":1775786345,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics CFO Abby Sarah Macnish Niven filed an initial Form 3 reporting indirect ownership of 454,545 ordinary shares via CASAM Investments Pty Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL8Ws14q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314644","title":"Alterity Therapeutics Ltd - End-of-Phase 2 FDA Meeting on Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314644?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:25","pubTimestamp":1774869900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA45G7VZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623316986","title":"Alterity Therapeutics Ltd - Receives Positive FDA Feedback Following Type C Meeting on Ath434 Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2623316986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623316986?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:17","pubTimestamp":1774865854,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623362996","title":"Alterity Therapeutics Receives Positive FDA Feedback After Type C Meeting on Planned Third-Phase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2623362996","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623362996?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:03","pubTimestamp":1774836187,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  received positive feedback following a type C meeting with the US Food and Drug Administration  on its planned third-phase development program for drug candidate ATH434 in multiple system atrophy , according to a Monday filing with the Australian bourse.MSA is a progressive neurodegenerative disorder affecting the autonomic nervous system and motor control.The meeting aims to align with the FDA regarding the readiness to start a phase three pivotal trial in MSA, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1923622291.USD","BK4588","BK4007","LU1815336091.USD","BK4139","LU0053671581.USD","BK4539","ATH.AU","LENZ","LU0757428866.USD","LU2125909759.SGD","LU0728928796.USD","BK7067","BK4585","BK4143","LU2125909916.SGD","LABU","MSA","LU2211815571.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854408","title":"Dogecoin (DOGE) Breaks Price Stalemate as History Signals Worst Is Over: What to Expect","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854408","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854408?lang=en_us&edition=fundamental","pubTime":"2026-03-25 14:52","pubTimestamp":1774421520,"startTime":"0","endTime":"0","summary":"Dogecoin (DOGE) is on track to close March in the green and end the bearish close of the past five months. As perCryptorank data, the meme coin is up by 3.04% and could finish the month on a value hig","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/dogecoin-doge-breaks-price-stalemate-as-history-signals-worst-is-over-what-to-expect","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/dogecoin-doge-breaks-price-stalemate-as-history-signals-worst-is-over-what-to-expect","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["TXXD","BK7067","BK4162","DOGE.USD.HKCC","ATH","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621171180","title":"Solana (SOL) Reclaims $90 Amid Golden Cross Setup, Where's Price Heading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621171180","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621171180?lang=en_us&edition=fundamental","pubTime":"2026-03-21 14:05","pubTimestamp":1774073100,"startTime":"0","endTime":"0","summary":"Solana  has rebounded in price and reclaimed the $90 level amid positive signals from the altcoin. This comes as a golden cross setup has formed on the asset’s technical chart. As perCoinMarketCap data, the development pushes Solana’s gain over the last seven days by 3.71%.Can Solana bulls push price to $96?","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/solana-sol-reclaims-90-amid-golden-cross-setup-wheres-price-heading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/solana-sol-reclaims-90-amid-golden-cross-setup-wheres-price-heading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["ATH","SOLT","SOL.AU","BK7083","BK7105","SOL.USD.HKCC","BK7062","SOLZ","BK4162","ATH.AU","TVL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618978669","title":"Shibarium Transactions Jump 148% Amid SHIB Price Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978669","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618978669?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:30","pubTimestamp":1773214200,"startTime":"0","endTime":"0","summary":"Shibarium, the layer-2 scaling solution of the Shiba Inu ecosystem, has seen a mild uptick in its transaction activities in a 24-hour period. While uncertainty lingers, this uptick lends credence to h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/shibarium-transactions-jump-148-amid-shib-price-consolidation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/shibarium-transactions-jump-148-amid-shib-price-consolidation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["ATH.AU","BK4162","ATH","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616319765","title":"Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2616319765","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616319765?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:04","pubTimestamp":1772622295,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics Ltd. has appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, with the role starting in March 2026. Claassen will retain his academic appointment at Vanderbilt University Medical Center while advising on the clinical development of Alterity’s neurodegenerative disease programs, including ATH434 in multiple system atrophy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4Hm4Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":55,"code":"91000000","status":"200"}]}}